SUMAVEL® DosePro® (regalized trademark of Zogenix, Inc.) is a needle-free, single-use, subcutaneous product that does not require assembly and that can deliver relief as early as 10 minutes after dosing in some patients.

Use of SUMAVEL® DosePro® for 54 migraine attacks in an open-label study was associated with clinically and statistically significant increases in satisfaction and confidence in therapy among triptan users not satisfied with current treatment.

In a population whose baseline score on the Migraine-Act identified them as needing a change in acute migraine therapy, SUMAVEL® DosePro® was associated with effective relief of migraine pain and associated symptoms.

Statistically significant and clinically relevant improvement in treatment satisfaction and confidence in therapy.

Efficacy of and satisfaction and confidence with SUMAVEL® DosePro® were consistently maintained during use for multiple migraine attacks.

Conclusions

To assess patient-rated satisfaction and efficacy with SUMAVEL® DosePro® and to assess its efficacy in the subset of patients from the open-label study described above who were identified based on scores on the Migraine-Act as requiring a change in acute migraine therapy.

Methods

Conclusions

The % patients (90% confidence interval) confident or very confident in treating migraine attacks increased from 22.2% (15.2, 30.6) at baseline to 57.6% (48.8, 66.6) at the end of the treatment period.

Pain outcomes reflected efficacy of SUMAVEL® DosePro® and were consistent across attacks for the associated symptoms of nausea, photophobia, and phonophobia were similar to those for pain relief (Table 2).

Across attacks, mean PPMQ-R scores improved from baseline to the end of the treatment period for Overall Satisfaction and the subscales of Efficacy and Functionality with no deterioration in Tolerability, but declined slightly for Ease of Use (Figure 1). Improvement in Overall Satisfaction was the criteria for clinical significance and was consistent across attacks (Table 1).

The % patients satisfied/very satisfied increased from baseline to the end of the treatment period for all global satisfaction domains (Figure 2).

Overall Satisfaction

Satisfaction with Medication Effectiveness

Satisfaction with Side Effects

End of Treatment Period

% Patients

0 20 40 60 80

Figure 3. % Patients with Pain Relief or Pain-Free Response Across Attacks (n=277) After Treatment with SUMAVEL® DosePro

Table 2. Efficacy Data for Attack

Data are summarized as % attacks for pain outcomes and as proportion (%) of attacks at each satisfaction category.

Table 1. Results by Migraine Attack

Data are summarized as mean (SD).